Chronic Refractory Gout Market Size
Gout is a condition where a waste product called uric acid builds up in the body. Normally, uric acid dissolves in the blood, gets processed by the kidneys, and leaves the body in the urine. A small proportion of uric acid is also excreted by the intestines. With gout, there is too much uric acid in the body, either because the body makes too much uric acid, or the kidneys cannot remove as much as should. According to the National Kidney Foundation, gout affected 8.3 million adults in the US, which includes 6.1 million men and 2.2 million women.
DelveInsight's "Chronic Refractory Gout Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Chronic Refractory Gout Market, historical and forecasted epidemiology, the pipeline insight as well as the Chronic Refractory Gout market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Chronic Refractory Gout Market Analysis
The market size of Chronic Refractory Gout is expected to increase during the forecasted period owing to the rising prevalence of gout in the 7MM.
The Chronic Refractory Gout market analysis section of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic Refractory Gout market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives a thorough detail of Chronic Refractory Gout market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Chronic Refractory Gout Epidemiology Forecast
The Chronic Refractory Gout epidemiology section covers insights about historical and current Chronic Refractory Gout patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognize the causes of current and forecasted Chronic Refractory Gout Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Chronic Refractory Gout Pipeline Analysis and Key Companies
The Chronic Refractory Gout Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Chronic Refractory Gout market or expected to get launched in the market during the study period. The analysis covers the Chronic Refractory Gout market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the Chronic Refractory Gout drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The key companies in the Chronic Refractory Gout market include:
Ampel BioSolutions
Selecta Biosciences
Horizon Therapeutics
And others.
Chronic Refractory Gout Therapies covered includes Azathioprine, SEL-212, Krystexxa, and many others.
Source: Chronic Refractory Gout Market Size